PHASE 2, OPEN-LABEL, LONG-TERM, EXTENSION (OLE) STUDY OF INFIGRATINIB, AN FGFR 1-3-SELECTIVE TYROSINE KINASE INHIBITOR, IN CHILDREN WITH ACHONDROPLASIA: PROPEL OLE

Registry ID

QBGJ398-203

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

QED THERAPEUTICS, INC.

Start date

2023-05-31

Last update

2022-10-20

Conditions

• ACHONDROPLASIA

Related clinical trials

• PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, PRECEDED BY A SINGLE ASCENDING DOSE PORTION AND A PHASE 2 OPEN-LABEL PORTION, TO EVALUATE THE SAFETY AND EFFICACY OF ORAL INFIGRATINIB IN INFANTS AND YOUNG CHILDREN WITH ACHONDROPLASIA
• A MULTICENTER, PHASE 2, DOSE-ESCALATION/DOSE-EXPANSION STUDY OF TYRA-300 IN CHILDREN WITH ACHONDROPLASIA WITH OPEN GROWTH PLATES: BEACH301
• ATTACH: A PHASE 2, MULTICENTER, LONG-TERM, OPEN LABEL EXTENSION TRIAL EVALUATING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS DOSES OF TRANSCON CNP ADMINISTERED ONCE WEEKLY IN CHILDREN AND ADOLESCENTS WITH ACHONDROPLASIA

View on source registry